摘要
目的研究伊马替尼对慢性髓系白血病(CML)患者骨髓细胞及白血病细胞系K562血管内皮生长因子(VEGF)表达的影响。方法采用ELISA检测伊马替尼作用前后CML骨髓细胞和K562细胞VEGF蛋白表达水平,实时荧光定量PCR检测伊马替尼对K562细胞VEGFmRNA表达的影响。结果CML患者骨髓单个核细胞在伊马替尼作用后VEGF蛋白表达量为(130.66±100.58)pg/ml,明显低于未加药组(269.11±176.79)pg/ml(P<0.01)。K562细胞VEGFmRNA和蛋白表达水平于伊马替尼作用后亦呈剂量依赖性下降。结论伊马替尼对CML患者VEGF的表达有明显抑制作用,提示该药对CML可能具有抗血管新生作用。
Objective To explore the effect of imatinib on the expression of vascular endothelial growth factor （VEGF） in the bone marrow cells of patients with chronic myeloid leukemia（CML） and K562 cell line. Methods The amount of VEGF protein in conditioned medium of bone marrow cells in CML and K562 cells was determined by ELISA before and after imatinib. VEGF gene expression levels in K562 cells were analyzed by real-time quantitative PCR. Results The VEGF concentration of cultural supernatants in CML bone marrow cells treated with imatinib was（130. 66±100. 58） pg/ml,which was significantly lower than （269. 11±176. 79） pg/mlin in those untreated （P〈0. 01）. Imatinib decreased the levels of VEGF mRNA and protein expression in K562 cells in a dose-dependent manner. Conclusion Imatinib markedly inhibits VEGF expression in patients with CML, and may be a potent inhibitor of angiogenesis in CML.
出处
《江苏医药》
CAS
CSCD
北大核心
2008年第11期1081-1083,共3页
Jiangsu Medical Journal
基金
江苏省临床医学中心开放课题基金资助项目(WKF07002)
